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doi:10.1016/j.ejvs.2010.12.007Abstract Aims: Angiotensin-converting enzyme (ACE) inhibitors have proven their ability to
affect vascular wall remodelling, in addition to their anti-hypertensive effects. The aim of this
study was to assess the impact of perindopril on the development of abdominal aortic aneu-
rysm (AAA) in a rat model, and its correlation to enzyme activities involved in vascular wall
remodelling.
Methods: The model of the decellularised aortic xenograft in Lewis rat was chosen. Rats were
randomised to two groups: group P fed with 3 mg kg1 of perindopril daily during 30 days, or
control group C (nZ 15 per group)). Rats were euthanised at 30 days for analysis. AAA growth
and histological changes in the aortic wall were measured by histomorphometry. Proteolytic
activities were measured by gelatin zymography of conditioned medium for activematrix
metalloproteinase 9/pro-matrix metalloproteinase 9 (MMP9/pro-MMP9) and activeMMP2/pro-
MMP2, and by quantitative immunofluorescence tissue for elastase and plasmin.
Results: The mean maximal diameter of AAAs at 30 days was significantly lower in the treated
group P compared with the control group C (2.5  1.0 vs. 4.9  2.1 mm; P < 0.01). The expan-
sion rate of AAAs after 30 days was significantly reduced in group P compared with group
C (36  14% vs. 67  23%; P < 0.01). Pro-MMP9 and MMP9 activities were significantly decreased
in relative intensity (RI) in group P compared with group C (0.43  0.64 RI vs. 1.02  0.61 RI,hirurgie Cardiaque et Vasculaire, Hoˆpital Europe´en Georges Pompidou, 20-40 rue Leblanc, 75908 Paris
gp.aphp.fr (J.-M. Alsac).
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Downregulation of Remodelling Enzymatic Activity Induced by an Angiotensin-converting Enzyme Inhibitor 475P Z 0.01; 0.18  0.57 RI vs. 0.66  1.19 RI, P Z 0.004). The activation rate of MMP2 was also
significantly lower in group P compared with group C (1.27  0.42 vs. 1.67  0.44; PZ 0.002).
Elastase and plasmin tissue activities were significantly lower in group P compared with group C,
respectively (3.9  3.3 vs. 5.8  3.7 IF min1 g1,and 25.9  23.9 vs. 49.1  38.7 IF min1 g1;
P < 0.05).
Conclusion: After 30 days of treatment by perindopril, a significant decrease in aneurysmal
degeneration of the decellularised aortic xenograft AAA model was observed. This phenomenon
appears to be induced by a downregulation of enzymes involved in the aortic wall remodelling
during aneurysmal degeneration.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Abdominal aortic aneurysms (AAAs) are characterised by
segmental dilatation of the aortic wall and pathologic
remodelling of the extracellular matrix.1 Although elastin
and collagen normally provide the resilience and tensile
strength needed for the aorta to withstand haemodynamic
stress, destruction of the elastic media is an early event in
aneurysmal degeneration, and collagen degradation is
considered necessary for aneurysm expansion and rupture.2
Experimental AAAs are associated with chronic transmural
inflammation and elevated local expression of enzymes
that mediate matrix protein degradation, including matrix
metalloproteinases (MMPs), elastase and plasminogen
activators.36 Pharmacologic strategies aimed at prevent-
ing matrix degradation may therefore have promise in the
management of small asymptomatic AAAs.7 Angiotensin-
converting enzyme (ACE) inhibitors are widely used in the
treatment of hypertension, congestive heart failure and
other cardiovascular disorders.8 Besides their vasodilatator
effects, these compounds are recognised as having
a substantial influence on connective tissue remodelling
after myocardial infarction or vascular wall injury.9,10 In
many circumstances, these effects arise through a direct
modification of fibroproliferative tissue healing rather than
haemodynamic changes alone, and they may involve inhi-
bition of ACE in the vessel wall, as opposed to the circu-
lating enzyme alone.11,12 Despite the widespread use of
ACE inhibitors in patients with cardiovascular disease, little
is known about their potential effects on aortic aneurysms.
A previous study by Liao et al.13 demonstrated that ACE
inhibitors have an important influence on experimental
aneurysmal degeneration, but that these effects are
distinct from changes in systemic haemodynamics alone or
events mediated solely by type 1 angiotensin II (ANG II)
receptors. However, their molecular, cellular and physio-
logic mechanisms remain to be elucidated.
In this study, we investigated the effect of a treatment
by an ACE inhibitor (perindopril) on the process of experi-
mental aneurysmal degeneration, and its correlation with
enzymatic activities involved in aortic wall remodelling.
Methods
Preliminary control study design
Fifteen Lewis rats normotensive without AAA were used for
a preliminary control study to determine the effect of the
treatment by perindopril (3 mg kg1 day1) during 1 month
on systemic haemodynamics and to show that ACE activitywas efficiency-inhibited at the dosage used in this partic-
ular model.
Haemodynamic measurements
The systolic blood pressure (SBP) was measured using the
tailecuff method (IITC Life Science), previously
described,14 in all 15 rats. Six individual recordings were
made in a 30-min period of stabilisation, and the mean of
these values was used to establish the pre-treatment
baseline conditions for each animal. Haemodynamic
measurements were repeated with the same technique
after 30 days of perindopril treatment.
Renin activity
One millilitre of blood was sampled on citrate at the time of
anaesthesia at day 0 and after 30 days of treatment by
perindopril. Blood samples were centrifuged (1500 rpm for
10 min), and plasma recuperated for analysis of plasma
renin activity (PRA). PRA was measured by radioimmuno-
assay of the angiotensin I (ANG-I) produced by incubation of
plasma at 37 C for 1 h.15
Study on experimental AAA models
We used the model of the decellularised aortic xenograft in
rat, as previously described.16,17 Animals were fed a stan-
dard diet. Animal care complied with the principles of
laboratory animal care formulated by the European Union,
and experimentation was carried out under the authority of
the French Agriculture Ministry (authorisation n75-214,
delivered 25 March 2003).
Graft preparation
The xenografts were abdominal aortas from male guinea
pigs (body weight (b. w.) 350 g, centre Ardenay, France).
Guinea pigs were anaesthetised with pentobarbital (5 mg
100 g1 b.w. intra-peritoneally) and a midline laparotomy
performed. A 1-cm-long segment of infrarenal aorta was
removed after ligature of collaterals under an operating
microscope and rinsed with 0.9% saline solution. The guinea
pig aortas were then incubated for 18 h at 37 C in 0.1%
sodium dodecyl sulphate (SDS) buffer with gentle agitation.
The SDS-treated aortas were then washed once with Triton
X-100, 0.1% in phosphate-buffered saline (PBS) for 24 h, and
4 times in PBS for 24 h. Decellularisation of the graft, using
this technique, has been verified by examination of fixed
sections with light and electron microscopy.16
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The graft recipients were inbred Lewis rats (b.w. 250 g,
CERJ, 53940 Le Genest St-Isle, France). An appropriate
length of recipient aorta was removed from below the renal
arteries and above the aortic bifurcation in Lewis rats. The
guinea pig aorta was inserted in an orthotopic position; and
two end-to-end interrupted anastomoses were performed
under an operating microscope with a 10/0 nylon non-
absorbable monofilament suture. Graft patency was veri-
fied, its width measured using a grid in the microscope
eyepiece, the laparotomy then closed and the rat returned
to its cage.
Experimental design
Thirty male Lewis rats and 30 guinea pigs were used for this
study. Simultaneously with transplantation (D0), the rats
were randomly allocated:
- to group P, perindopril-administered group (n Z 15);
a dose of 3 mg kg1 of perindopril was fed orally on
a daily basis during 30 days; and
- to group C, control group (n Z 15); a regular diet was
fed to this group.
The rats were sacrificed at 30 days (D30) for analysis
(Fig. 1). Blood samples were taken before sacrifice and
aortic tissue was collected at the time of sacrifice.
Blood samples
One millilitre of blood was sampled on citrate at the time of
sacrifice (D30). Blood samples were quickly centrifuged
(1500 rpm for 10 min), and plasma recuperated and frozen
for further analysis.
Macroscopic analysis and in vivo measurements
In vivo measurements were initially performed at D0 after
aortic declamping, with a grid on the microscope eyepiece.
The grafts were harvested 30 days after surgery. Under deep
pentobarbital anaesthesia, a laparotomy was performed andFigure 1 Median laparotomyat timeof sacrifice (D30) showing
the abdominal aortic aneurysm (calibrated by thewhite arrows).the graft gently dissected. The width of the graft was again
measured in vivo, using the same initial grid in the micro-
scope eyepiece. The variation of graft diameter between D0
and D30 was taken as the main evaluation criterion.
After clamping the aorta, the graft was removed and rinsed
in PBS.
Morphometry analysis
After in vivomeasurements, aneurysms were harvested and
cut transversally in two parts to obtain morphometric data
and determine proteolytic activities present in the tissue.
One part of the aneurysm was fixed in a 3.7% para-
formaldehyde solution and embedded in paraffin. Serial
5-mm sections were stained with Picrosirius Red solution
and microphotographs were analysed to calculate different
morphometric data: aneurysm diameter, medial and
intimal thickness and lumen diameter (Fig. 1).
Determination of Pro-MMP9, active MMP9,
Pro-MMP2 and active MMP2 activities
The second half of the aneurysm was incubated in RPMI
1640 medium (Gibco) for 24 h at 37 C (2 ml mg1 of wet
tissue). The conditioned media were then used to deter-
mine these secreted MMPs’ activities.18 Proteolytic activi-
ties present in conditioned media and in plasma are
determined with gelatin zymography (Fig. 2). One micro-
litre (ml) of plasma or 2 ml of conditioned medium were
analysed by electrophoresis on 10% sodium dodecyl
sulphate-polyacrylamide gels containing 1 mg ml1 gelatin
as previously described.19 After incubation at 37 C for 19 h,
gels were stained with Coomassie blue and then transferred
in a 10% acetic acid and 30% ethanol solution to reveal lytic
bands, appearing as clear bands on a dark blue background.
The gels were kept in a 10% acetic acid solution and lysis
areas, corresponding to gelatinolytic activities, were
quantified in relative intensity (RI) by densitometry with
ImageJ 1.43n software and compared with a positive
control (Fig. 3).Figure 2 Microphotograph X 10 of aneurysm stained with
picrosirius red. Intima and Media can be differentiated by their
different stain.
Figure 3 Typical zymograms of plasma (A) and conditioned media (B). These zymograms show profiles of a control rat and a rat
treatedwith Perindopril, obtainedwith their plasma or their conditionedmedium. Lytic bands corresponding to pro form of MMP2 and
MMP9 can be observed in both zymograms (A, B) whereas active form lytic bands are just observed with conditioned medium (B).
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aortic tissue
After incubation, aneurysmal tissues used for conditioned
media were also used to measure plasmin and elastase
activities. Plasmin and elastase activities in aneurysmal tissue
weremeasured by spectrofluorometry, using their fluorogenic
substrates (respectively: MeOSuceAlaePheeLyseAMC TFA,
Bachem; Elastase Substrate V Fluorogenic, MeOSuce
AAPVeAMC, Calbiochem). Measurement was made with
aortic tissues used for the conditioned medium, after incu-
bation. Ten milligrammes of tissue were put in hydrolysis
buffer (0.05 M of HEPES (4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid), 0.75M of NaCl and 0.05% of IGEPAL
(octylphenoxypolyethoxyethanol) CA-630, SigmaeAldrich)
with or without enzyme inhibitor (99 mM of plasmin inhibitor:
DeValePheeLys chloromethyl ketone dihydrochloride,
Calbiochem; 25 mM of Elastase Inhibitor III, Calbiochem).
Then, fluorogenic substrates were added, to have in the
solution 40 mM of elastase substrate or 4 mM of plasmin
substrate. Within 2 h, fluorescence was measured 6 times
(Fluorescence Spectrophotometer F-2000, Hitachi; excita-
tion wavelength: 380 nm; emission wavelength: 460 nm) and
enzyme activity was expressed in fluorescence intensity as
a function of time and tissue weight (FI min1 mg1).
Statistical analysis
Results were expressed as median (range). The percentage
of diameter increase was calculated as follows: (diameter
at harvest  diameter at grafting)  100/diameter at
grafting. Comparisons between both groups were madeTable 1 Macroscopic analysis of aortas diameters at D0 and D3
Time Groups Number R
Day 0 C 15 1
P 15 1
Day 30 C 15 2
P 15 1
a p Z 0.0005 compared to the group C.using the non-parametric ManneWhitney U test (Statview,
version 4.5). Simple regression analysis was used to test for
correlations between various parameters. A P value <0.05
was considered as significant.
Results
Blood pressure and rennin activity
There was a non-significant small decrease in SBP measured
at D0, compared with SBP measured after 30 days of treat-
ment by perindopril (112  10 mmHg vs. 107  12 mmHg,
respectively).
ACE activitywas foundefficiency-inhibited after 30 days of
treatment by perindopril, with a significant increase of PRA
reflected by ANG-I measurements at baseline and after 30
days of treatment (3.7 1.1 vs. D30Z 22.6 5.5 ngml1 h1,
respectively; P < 0.0001).
Macroscopic analysis of AAA and in vivo
measurements (Table 1)
The graft diameter increased significantly in both groups
between D0 and D30 from 1.6 to 4.9 in controls (P < 0.001),
and from 1.6 to 2.5 in group P (P < 0.05). The in vivo
diameter of aneurysmsmodels at D30 was significantly lower
in group P compared with group C (P < 0.001).
Morphometric analysis (Table 2)
The aneurysms’ diameter and the lumen area of aortas
were significantly lower in group P compared with group0 in each analysed groups.
ange Median Standard deviation
.5e1.8 1.6 0.25
.5e1.9 1.6 0.22
.3e6.4 4.9 2.13
.8e3.8 2.5a 1.01
478 J.-M. Alsac et al.C (P < 0.001). There was no significant difference of intimal
and medial thickness between both the analysed groups
(P Z 0.38 and P Z 0.58, respectively).
Pro-MMP9, active MMP9, Pro-MMP2 and active
MMP2 activities
The quantification of pro-MMP9 and active MMP9 at D30 in
conditioned media, measured in RI compared with a positive
control, was significantly lower in group P compared with
group C: respectively, 0.427 (0.027e1.228) versus 1.017
(0.246e1.297), PZ 0.013; and 0.181 (0.033e1.246) to 0.658
(0.061e3.617), P Z 0.004. The quantification of pro-MMP2
and active MMP2 at D30, in RI compared with a positive
control, did not significantly differ between group P and
group C: respectively, 3.272 (1.549e5.777) versus 3.420
(2.213e7.013), P > 0.05; and 10.204 (4.797e23.183) to
8.322 (3.669e15.450), P> 0.05. The activation rate of MMP2
measured by the ratio pro-MMP2/active MMP2 was signifi-
cantly lower in group P comparedwith group C: respectively,
59% (32e70%) versus 65% (52e128%), PZ 0.044.
Elastase and plasmin activities in aortic tissue
Leucocyte elastase and plasmin tissue activities were
significantly lower in group P compared with group C,
respectively (3.9  3.3 vs. 5.8  3.7 IF min1 g1, and
25.9  23.9 vs. 49.1  38.7 IF minv1g1; P < 0.05).
Discussion
After 1monthof oral treatment byperindopril (ACE inhibitor)
at 3 mg kg1 day1, a significant decrease in aneurysmal
degeneration of the decellularised aortic xenograft AAA
model was observed. This phenomenon seemed to be
induced by a downregulation of the enzymatic activities
involved in the aortic wall remodelling during aneurysmal
degeneration in this model.
These results emphasise the potential effects of an ACE
inhibitor (perindopril) on the development of aortic aneu-
rysms. AAA is a common life-threatening disease for which
no pharmacologic treatment yet exists. ACE inhibitors are
widely used in the management of cardiovascular disorders
that often occur in conjunction with AAAs. Effects of ACE
inhibitors on the remodelling of cardiovascular tissues may
also have implications for the pathophysiologic mechanisms
of aneurysm disease. By using an aortic xenograft rodentTable 2 Morphometric analysis of aneurysms samples in each g
Measurements Group Number
Diameter (mm) C 15
P 15
Lumen area (mm2) C 15
P 15
Medial thickness (mm) C 15
P 15
Intimal thickness (mm) C 15
P 15
a p < 0.001 compared to the group C.model, we found out that a treatment by this ACE inhibitor
effectively prevented in vivo the aneurysmal degeneration
of the abdominal aorta.
In humans, AAA is a particular form of atherothrombosis
characterised by a predominant role of protease including
MMPs,20,21 and serine protease among which the fibrinolytic
system22 and the leucocyte elastase23 predominate.
Earlier studies on rodent models of AAA have demon-
strated that chronic transmural inflammation and elevated
expression of MMPs make essential contributions to the
development of elastase-induced aneurysms in rats.24,25 By
using an elastase-induced rodent model, Liao et al.13 found
that treatment with each of three different ACE inhibitors
(captopril, lisinopril and enalapril) prevented the develop-
ment of aneurysms in vivo. Some hypotheses of biological
mechanisms were discussed by the authors but needed to
be investigated further. Although these ACE inhibitors did
not appear to alter the influx of mononuclear inflammatory
cells into the elastase-injured aortic wall, their inhibitory
effects on aortic dilatation were associated with the pres-
ervation of aortic medial elastin.
These findings were consistent with the notion that
matrix degradation is critical in aneurysm development, and
the mechanisms underlying these effects clearly appeared
to be distinct from haemodynamic alterations alone. The
results of our preliminary control study confirmed these
observations as no significant haemodynamic modification
was found on SBP after 1 month of treatment by perindopril
on normotensive rats. One of their biological explanations
was highlighted in our study by the correlation between the
downregulation of local expression of a specific MMP (9)
induced by the ACE inhibition and the aneurysm degenera-
tion. ACE inhibitors such as perindopril specifically bind zinc,
which is an essential cofactor for MMPs implicated in the
metabolism of elastin and collagen. Recent studies indicate
that the proteinase-inhibiting effects of at least some ACE
inhibitors can also extent to MMPs and that these effects can
be sufficient to inhibit MMP-mediated processes such as
tumour growth and metastasis, angiogenesis and experi-
mental heart failure.2529 Allaire et al. also demonstrated
that local blockade of MMPs by tissue inhibitor of metal-
loproteinases-1.
(TIMP-1),30 and plasmin formation by plasminogen acti-
vator inhibitor-1 (PAI-1) overexpression31 prevented the
development of experimental aneurysm in the xenograft
model. Through this pathway, ACE inhibitors could have an
impact on the expression of MMPs and reduce chronic trans-
mural inflammation involved in aneurysmal degeneration.roup at D30.
Range Median Standard deviation
3.0e8.1 5.61 3.40
2.6e4.5 2.98a 0.93
0.8e5.2 2.15 2.55
0.5e1.1 0.65a 0.26
77.5e221.6 125.91 100.40
60.3e193.7 128.50 33.89
31.7e149.3 51.09 17.79
19.0e109.6 44.71 14.90
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ANG-I to ANG-II, the results of this study suggest that ANG-II
plays an important role in the pathophysiology of aneu-
rysmal degeneration. Our preliminary study confirmed that
ACE activity was efficiency-inhibited at the dosage used in
our particular model, resulting in a significant increase of
PRA and plasmatic ANG-I. This notion is also supported by
two recent experimental studies in genetically altered
mice. Nishijo et al.32 found that transgenic overexpression
of ANG-II is associated with the development of aneurysmal
aortic lesions in hypertensive animals placed on a high-salt
diet. These lesions had histological features of aortic
dissection and they were frequently complicated by
rupture, but there was no association between the occur-
rence of these lesions and further alterations in the
hypertension exhibited by these animals. More recently,
Daugherty et al.33 found that sustained infusion of ANG-II
leads to aneurysmal lesions in the atherosclerosis-prone
apoEe/e mouse, and that this occurs in the absence of
systemic hypertension. The aortic lesions included chronic
inflammation in the outer aortic wall and breaks in the
elastic media, but were not associated with atherosclerotic
plaques, thereby bearing similarity to the type of aneu-
rysmal degeneration that occurs in the elastase perfusion
model. Because aneurysms were not observed in apoE-
deficient mice in the absence of ANG-II infusion, the
authors concluded that the combination of hyperlipidaemia
and ANG-II had accelerated the development of aortic wall
inflammation. This is consistent with evidence that ANG-II
has a direct effect on monocyte recruitment and macro-
phage activation,3438 explaining the downregulation
effect of ACE inhibition on local cellular inflammation. The
decrease of local tissue activities of elastase and plasmin
induced after 1 month of treatment by perindopril might
therefore reflect a mechanism of downregulation of the
macrophage activation usually involved in aneurysmal
dilatation.
Limitations of our study include the influence of a low-
ered blood pressure, and the effect of the dose of peri-
ndopril on aortic ACE inhibition. Even though not
statistically significant, our data are suggestive of the fact
that blood pressure has been lowered by perindopril, and
we cannot exclude that some of the effects we observed
were mediated by blood pressure. In addition, although we
have evidence that the dose of perindopril effectively
inhibits circulating ACE, we have no direct evidence as
regards tissue penetration and its effect on aortic ACE.
Furthermore, we cannot conclude that ACE inhibitors
suppress AAA, but that one of them, perindopril, decreases
the experimental aneurysmal degeneration process. This
difference should be taken into account for further clinical
applications on small aneurysms. We should therefore only
expect ACE inhibitors to have an influence on AAA growth to
rupture. A retrospective case-control study using a large
Canadian administrative database39 showed that, for
patients admitted to hospital with a diagnosis of AAA, those
taking ACE inhibitors were less likely to present with
ruptured aneurysm. As a consequence, these authors sug-
gested that ACE inhibition might also be associated with
a reduction in aneurysm growth rates and that a pilot trial
was indicated. But a recent analysis of the patients
prospectively enrolled and followed by the UK SmallAneurysm Trial and study40 shows surprisingly an associa-
tion between ACE inhibition and increased aneurysm
growth rate. The data were collected over 10 years ago,
and although the same ACE inhibitors (captopril, enalapril
and lisinopril) are still being used, newer ACE inhibitors
such as ramipril or perindopril were not prescribed at this
time. However, in the Canadian study of aneurysm rupture,
there was no evidence for a doseeresponse relationship as
regards protection against aneurysm rupture: lower doses
seemed more efficacious than higher doses of ACE inhibi-
tors and those who had discontinued ACE inhibitors, 3e12
months earlier, had a much increased risk of presenting
with rupture.41 It remains possible that ACE inhibitors have
contrasting effects on aneurysm growth and rupture.
In conclusion, this study confirmed that perindopril, an
ACE inhibitor, has an important influence on experimental
aneurysmal degeneration. This compound appears to ach-
ieve this effect through a downregulation of the vascular
remodelling enzymatic activity, although blood pressure
reduction may be contributory. These experimental obser-
vations fuel the recent controversy on how ACE inhibitors
influence aneurysm expansion or rupture in patients diag-
nosed with asymptomatic AAA. A randomised trial on the
effect of ACE inhibitors on aneurysm growth rates is needed
to assess whether this class of drug protects or harms the
patient with an AAA.
Funding
This experimental study was funded by Laboratoire SERV-
IER’s grant for research on aneurysmal physiopathology and
therapeutics.
U698 is supported by FAD. FP.7. EU project (Health-F2-
2008-200647) at http://www.fighting-aneurym.org.
Conflict of Interest
None.Acknowledgements
This article has been presented at the European Society for
Vascular Surgery (ESVS) 2010 in Amsterdam, the
Netherlands.
References
1 Thompson RW, Lee JK, Curci JA. The pathobiology of abdominal
aortic aneurysms. In: Gewertz BL, editor. Surgery of the aorta
and its branches. Philadelphia: W.B. Saunders; 2000. p. 75e106.
2 Dobrin PB, Mrkvicka R. Failure of elastin or collagen as possible
critical connective tissue alterations underlying aneurysmal
dilatation. Cardiovasc Surg 1994;2:484e8.
3 Thompson RW, Parks WC. Role of matrix metalloproteinases in
abdominal aortic aneurysms. Ann N Y Acad Sci 1996;800:
157e74.
4 Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plas-
minogen activators in aortic aneurysmal and occlusive disease.
J Vasc Surg 1994;19:865e72.
5 Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P,
et al. Urokinase-generated plasmin activates matrix
480 J.-M. Alsac et al.metalloproteinases during aneurysm formation. Nat Genet
1997;17:439e44.
6 Anidjar S, Dobrin PB, Chejfec G, Michel JB. Experimental study
of determinants of aneurysmal expansion of the abdominal
aorta. Ann Vasc Surg 1994;8:127e36.
7 Thompson RW. Basic science of abdominal aortic aneurysms:
emerging therapeutic strategies for an unresolved clinical
problem. Curr Opin Cardiol 1996;11:504e18.
8 Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibi-
tors. Circulation 1998;97:1411e20.
9 Michel JB. Tissue consequence of renin-angiotensin system
activation. Bull Acad Natl Med 2004;188(4):611e9. discussion
620.
10 Michel JB. Renin-angiotensin system and vascular remodelling.
Med Sci (Paris) 2004;20:409e13.
11 Kim S, Iwao H. Molecular and cellular mechanisms of angio-
tensin II-mediated cardiovascular and renal diseases. Pharma-
col Rev 2000;52:11e34.
12 Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE.
Induction of angiotensin converting enzyme in the neointima
after vascular injury. Possible role in restenosis. J Clin Invest
1994;93:339e46.
13 Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW.
Suppression of experimental abdominal aortic aneurysms in the
rat by treatment with angiotensin-converting enzyme inhibi-
tors. J Vasc Surg 2001;33:1057e64.
14 Whitesall SE, Hoff JB, Vollmer AP, D’Alecy LG. Comparison of
simultaneous measurement of mouse systolic arterial blood
pressure by radiotelemetry and tail-cuff methods. Am J Physiol
2004;286:H2408e15.
15 Menard J, Catt KJ. Measurement of renin activity, concentra-
tion and substrate in rat plasma by radioimmunoassay of
angiotensin I. Endocrinology 1972;90:422e30.
16 Allaire E, Guettier C, Bruneval P, Plissonnier D, Michel JB. Cell-
free arterial grafts: morphologic characteristics of aortic
isografts, allografts, and xenografts in rats. J Vasc Surg 1994;
19:446e56.
17 Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U,
et al. Renewal of mural thrombus releases plasma markers and
is involved in aortic abdominal aneurysm evolution. Am J Pathol
2006;168:1022e30.
18 Duran MC, Mas S, et al. Proteomic analysis of human vessels:
application to atherosclerotic plaques. Proteomics 2003;3:
973e8.
19 Badier-Commander C, Verbeuren T, Lebard C, Michel JB,
Jacob MP. Increased TIMP/MMP ratio in varicose veins:
a possible explanation for extracellular matrix accumulation.
J Pathol 2000;192:105e12.
20 Sakalihasan N, Heyeres A, Nusgens BV, Limet R, Lapie`re CM.
Modifications of the extracellular matrix of aneurysmal
abdominal aortas as a function of their size. Eur J Vasc Surg
1993;7:633e7.
21 Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapie`re CM.
Activated forms of MMP2 and MMP9 in abdominal aortic aneu-
rysms. J Vasc Surg 1996;24:127e33.
22 Houard X, Rouzet F, Touat Z, Philippe M, Dominguez M,
Fontaine V, et al. Topology of the fibrinolytic system within the
mural thrombus of human abdominal aortic aneurysms. J Pathol
2007;212:20e8.
23 Fontaine V, Touat Z, Mtairag el M, Vranckx R, Louedec L,
Houard X, et al. Role of leukocyte elastase in preventing
cellular re-colonization of the mural thrombus. Am J Pathol
2004;164:2077e87.
24 Anidjar S, Dobrin PB, Eichorst M, Graham GP, Chejfec G.
Correlation of inflammatory infiltrate with the enlargement of
experimental aortic aneurysm. J Vasc Surg 1992;16:139e47.25 Halpern VJ, Nackman GB, Gandhi RH, Irizarry E, Scholes JV,
Ramey WG, et al. The elastase infusion model of experimental
aortic aneurysms: synchrony of induction of endogenous
proteinases with matrix destruction and inflammatory cell
response. J Vasc Surg 1994;20:51e60.
26 Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril
inhibits the 72 kDa and 92 kDa matrix metalloproteinases.
Kidney Int 1993;44:1266e72.
27 Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB,
Johnson MD, et al. Captopril inhibits angiogenesis and slows the
growth of experimental tumors in rats. J Clin Invest 1996;98:
671e9.
28 Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of
gelatinase A (MMP-2) by batimastat and captopril reduces tumor
growth and lung metastases in mice bearing Lewis lung carci-
noma. Int J Cancer 1999;81:761e6.
29 McElmurray III JH, Mukherjee R, New RB, Sampson AC, King MK,
Hendrick JW, et al. Angiotensin-converting enzyme and matrix
metalloproteinase inhibition with developing heart failure:
comparative effects on left ventricular function and geometry.
J Pharmacol Exp Ther 1999;291:799e811.
30 Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local
overexpression of TIMP-1 prevents aortic aneurysm degenera-
tion and rupture in a rat model. J Clin Invest 1998;102:
1413e20.
31 Allaire E, Hasenstab D, Kenagy RD, Starcher B, Clowes MM,
Clowes AW. Prevention of aneurysm development and rupture
by local overexpression of plasminogen activator inhibitor-1.
Circulation 1998;98:249e55.
32 Nishijo N, Sugiyama F, Kimoto K, Taniguchi K, Murakami K,
Suzuki S, et al. Salt-sensitive aortic aneurysm and rupture in
hypertensive transgenic mice that overproduce angiotensin II.
Lab Invest 1998;78:1059e66.
33 Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes
atherosclerotic lesions and aneurysms in apolipoprotein
E-deficient mice. J Clin Invest 2000;105:1605e12.
34 Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II
activates the proinflammatory transcription factor nuclear
factor-kB in human monocytes. Biochem Biophys Res Commun
1999;257:826e8.
35 Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G,
Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition
prevents arterial nuclear factor-kappa B activation, monocyte
chemoattractant protein-1 expression, and macrophage infil-
tration in a rabbit model of early accelerated atherosclerosis.
Circulation 1997;95:1532e41.
36 Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM.
Angiotensin II induces monocyte chemoattractant protein-1
gene expression in rat vascular smooth muscle cells. Circ Res
1998;83:952e9.
37 Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human
peripheral monocytes by angiotensin II. FEBS Lett 1994;347:
178e80.
38 Kim JA, Berliner JA, Nadler JL. Angiotensin II increases mono-
cyte binding to endothelial cells. Biochem Biophys Res Commun
1996;226:862e8.
39 Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-
converting enzyme inhibitors and aortic rupture: a population-
based case-control study. Lancet 2006 Aug 19;368(9536):
659e65.
40 Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM,
Powell JT. Use of angiotensin converting enzyme inhibitors is
associated with increased growth rate of abdominal aortic
aneurysms. J Vasc Surg 2010;52:1e4.
41 Lederle FA, Taylor BC. ACE inhibitors and aortic rupture. Lancet
2006;368:1571.
